We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Adaptive Biotechnologies (ADPT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Adaptive Biotechnologies is a member of the Medical sector. This group includes 1010 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adaptive Biotechnologies is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ADPT's full-year earnings has moved 8.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ADPT has moved about 15.4% on a year-to-date basis. In comparison, Medical companies have returned an average of -3.8%. This means that Adaptive Biotechnologies is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Bio-Rad Laboratories (BIO - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 4.9%.
In Bio-Rad Laboratories' case, the consensus EPS estimate for the current year increased 2.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Adaptive Biotechnologies is a member of the Medical - Biomedical and Genetics industry, which includes 512 individual companies and currently sits at #56 in the Zacks Industry Rank. On average, this group has lost an average of 13.6% so far this year, meaning that ADPT is performing better in terms of year-to-date returns.
In contrast, Bio-Rad Laboratories falls under the Medical - Products industry. Currently, this industry has 82 stocks and is ranked #77. Since the beginning of the year, the industry has moved +14.1%.
Adaptive Biotechnologies and Bio-Rad Laboratories could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Adaptive Biotechnologies (ADPT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Adaptive Biotechnologies is a member of the Medical sector. This group includes 1010 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adaptive Biotechnologies is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ADPT's full-year earnings has moved 8.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ADPT has moved about 15.4% on a year-to-date basis. In comparison, Medical companies have returned an average of -3.8%. This means that Adaptive Biotechnologies is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Bio-Rad Laboratories (BIO - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 4.9%.
In Bio-Rad Laboratories' case, the consensus EPS estimate for the current year increased 2.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Adaptive Biotechnologies is a member of the Medical - Biomedical and Genetics industry, which includes 512 individual companies and currently sits at #56 in the Zacks Industry Rank. On average, this group has lost an average of 13.6% so far this year, meaning that ADPT is performing better in terms of year-to-date returns.
In contrast, Bio-Rad Laboratories falls under the Medical - Products industry. Currently, this industry has 82 stocks and is ranked #77. Since the beginning of the year, the industry has moved +14.1%.
Adaptive Biotechnologies and Bio-Rad Laboratories could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.